Literature DB >> 17387475

[Diagnosis and differential diagnosis of granulosa cell tumor].

D Schmidt1, F Kommoss.   

Abstract

Clinically and morphologically, two types of granulosa cell tumor can be distinguished, the more frequent adult type and the juvenile type. In the adult type, different growth patterns can be observed: microfollicular (most frequent, characterized by Call-Exner bodies), macrofollicular, trabecular, insular, solid-tubular, gyriform and diffuse (sarcomatoid). The juvenile type is characterized by solid and follicular structures. The neoplastic granulosa cells in the adult type have limited cytoplasm and haphazardly arranged angular, pale, mostly grooved nuclei. In the juvenile type, the cells have ample eosinophilic cytoplasm and polymorphic, sometimes bizarre nuclei, which are usually non-grooved. The number of mitoses in the adult type usually does not exceed 2/10 HPF, whereas it is considerably higher in the juvenile type, including atypical mitoses. A common feature in both types of tumor is the expression of inhibin-alpha, calretinin and CD 99. Epithelial membrane antigen is negative. Molecular genetics has demonstrated loss of heterozygosity at 19p13.3 in 52% of the cases. Besides chromosomal aberrations, there are a large number of cytogenetic anomalies. The most important prognostic factor in both types of tumor is tumor stage. Whereas recurrences in the adult type can develop even after decades, in the juvenile type they usually occur during the first 3 years after diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17387475     DOI: 10.1007/s00292-007-0908-8

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  24 in total

1.  Immunoreactivity of ovarian juvenile granulosa cell tumours with epithelial membrane antigen.

Authors:  W G McCluggage
Journal:  Histopathology       Date:  2005-02       Impact factor: 5.087

2.  Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody.

Authors:  K T Loo; A K Leung; J K Chan
Journal:  Histopathology       Date:  1995-10       Impact factor: 5.087

3.  Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization.

Authors:  Yue-Shan Lin; Hock-Liew Eng; Yee-Jee Jan; Herng-Sheng Lee; William L Ho; Chiou-Ping Liou; Wen-Yu Lee; Ching-Cherng Tzeng
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

Review 4.  Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.

Authors:  Robert H Young
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

5.  Histopathological prognostic factors of adult granulosa cell tumors of the ovary.

Authors:  T Fujimoto; N Sakuragi; K Okuyama; T Fujino; K Yamashita; S Yamashiro; M Shimizu; S Fujimoto
Journal:  Acta Obstet Gynecol Scand       Date:  2001-11       Impact factor: 3.636

6.  Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases.

Authors:  R H Young; G R Dickersin; R E Scully
Journal:  Am J Surg Pathol       Date:  1984-08       Impact factor: 6.394

7.  Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature.

Authors:  N Nakashima; R H Young; R E Scully
Journal:  Arch Pathol Lab Med       Date:  1984-10       Impact factor: 5.534

8.  Immunohistochemical phenotype of ovarian granulosa cell tumors: absence of epithelial membrane antigen has diagnostic value.

Authors:  M J Costa; P B DeRose; L M Roth; R J Brescia; C J Zaloudek; C Cohen
Journal:  Hum Pathol       Date:  1994-01       Impact factor: 3.466

Review 9.  Clinical review of 63 cases of sex cord stromal tumors.

Authors:  V Zanagnolo; B Pasinetti; E Sartori
Journal:  Eur J Gynaecol Oncol       Date:  2004       Impact factor: 0.196

10.  Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.

Authors:  Kazim Uygun; Adnan Aydiner; Pinar Saip; Mert Basaran; Faruk Tas; Zafer Kocak; Maktav Dincer; Erkan Topuz
Journal:  Am J Clin Oncol       Date:  2003-10       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.